article
A significant proportion of patients with rheumatologic disease are of reproductive age, therefore, navigating reproductive health is now widely recognized as a fundamental component of modern rheumatology care.
Recent News
At APLAR 2026 in Seoul, the OA special interest group offered a whirlwind overview of IA injectables from Dr. Gun-il Im (Dongguk University, Korea). The products fall into three tiers: symptom-modifying, biologic/regenerative and structure-oriented. The pipeline is encouraging, but the evidence is uneven and often thin.Read Article
Dr. John Cush
Tweet
THe the International Federation of Psoriasis Associations has announced that the 8th World Psoriasis & Psoriatic Arthritis Conference will be taking place in Stockholm on 20–22 May 2027. Registration is open. https://t.co/lq5XdcZlki https://t.co/AYGCnwzeue https://t.co/fy6UUCbcxf
Peter Nash
Tweet
AxSpA SIG Baraliakos - CD74 abs in SpA - what other abs need exploration?
@RheumNow #APLAR2026 https://t.co/rftgYQH4mX
sheila
Tweet
Key messages from Dr. Vaidya’s talk:
- Assocn’s of hyperuricemia or gout with MetS shows a bidirectional trend
- Causality: MetS as an upstream driver for gout devt
Going beyond jt dse & ULT. What addt’l assessments do you do for your gout pts?
@RheumNow #APLAR2026 https://t.co/M6XVoRQ5rz
Jiha Lee
Tweet
Perspective from dentists on SjD dry mouth: muscarinic agonists (pilocarpine, cevimeline) help, but side effects limit use. Two ways to improve it: split pilocarpine dosing (2.5 mg four times daily) and a cevimeline mouth rinse in 6 or more divided doses. #APLAR26 @RheumNow https://t.co/phiLD0qaoR
Jiha Lee
Tweet
@RheumNow Do the two fixes work? Split pilocarpine (n=20 SjD, 4 weeks): sweating severity 3.7 to 1.7 (p<0.001), oral dryness VAS 61.0 to 43.6 (p=0.011). Cevimeline rinse (n=12 SjD): unstimulated salivary flow higher than juice control at 1 and 2 h. Small studies. #APLAR26 @RheumNow https://t.co/LEDHFGwh8Q
sheila
Tweet
Lupus/LN should not be a sole indication for a C-section
C-section should be reserved for obstetric indications.
Adapt a multidisciplinary approach.
@RheumNow #APLAR2026 https://t.co/vrXeNP9xLI
sheila
Tweet
There is physiologic proteinuria in pregnancy so be careful before attributing a rise of levels to active LN
LN flare vs. pre-eclampsia: both can present w/ HTN, edema, low plts and inc crea.
> monitor C3 changes during each trimester of pregnancy
@RheumNow #APLAR2026 https://t.co/Pp6GGeLPC6
Jiha Lee
Tweet
Monitoring ILD in SjD: reassess risk at every visit. High risk with disease duration under 1 year: PFTs every 3-6 months, HRCT at 1 year. Lung biopsy has no role in diagnosis, except for atypical HRCT features or to exclude malignancy. #APLAR26 @RheumNow https://t.co/tFPNi0S8y8
sheila
Tweet
The growing unmet needs of repro health in the @APLAR_org region lead to dev’t of new consensus statements
Provides a practical guide for rheums focusing on key areas like preconception, meds safety in pregnancy & men w/AIRDs planning to become fathers etc
@RheumNow #APLAR2026 https://t.co/xCKmpcD4ma
Jiha Lee
Tweet
Same molecule, different route, different persistence: golimumab IV persisted 4.44 yrs vs 2.07 for SC in biologic-naive RA (n=9,464, Korean claims). Is it the route, or differenntial out of pocket cost, or supervised dosing and better adherence? P#240 #APLAR26 @RheumNow
Jiha Lee
Tweet
Older adults with RA on JAKi: filgotinib may carry a lower zoster risk than others. Is it JAK1 selectivity? UPA (available in the US) is also selective. Dose, zoster vaccination status and a mixed comparator group may matter. Day 3 Abst Session 7 #APLAR26 @RheumNow https://t.co/5ri4shAHnV
sheila
Tweet
This interesting study by @doktora_ging et al describes the notable differences in skin lesions bet Filipino vs caucasian.
Fil skin: darker lesions, marked contrast bet hypo/hyperpigmentation, more gray & black psor plaques
Practical & informative.
@RheumNow #APLAR2026 https://t.co/A1dyFRNkwV
sheila
Tweet
Guidelines similar for GC use in pregnancy.
For @APLAR_org , non-fluorinated gcs are recommended and much lower doses of prednisone <5mg/day as the target with IV MP preferred for severe disease.
Universal recos to monitor BP, glucose and steroid-related SEs
@RheumNow #APLAR https://t.co/FrQEsbLbOk
article
Sun Pharmaceuticals announced Friday that the FDA has approved its IL-23 inhibitor, tildrakizumab (Ilumya) for use in patients with active psoriatic arthritis. This agent is already FDA approved for plaque psoriasis, and joins guselkumab and risankizumab as the third IL-23 inhibitor approved for use in PsA.
Dr. John Cush
Tweet
Does IVIG have a Role in Scleroderma?
A recent systemic review and meta-analysis by Jozelio Freire de Carvalho and colleagues analyzed the available literature on this therapy. This study, published in Frontiers in Immunology in October 2026, evaluated the available evidence https://t.co/a8J2UT2I7Y
Dr. John Cush
Tweet
Beyond Chondrocalcinosis - What’s New in CPPD Disease
An overview of calcium pyrophosphate deposition (CPPD) disease by Sara Tedeschi presents our evolving understanding of CPPD with advances affecting nomenclature, classification, imaging, genetics, long-term outcomes and https://t.co/HmDgB9nNbm
Dr. John Cush
Tweet
Tocilizumab is effective in glucocorticoid-resistant adult-onset Still’s dz. 40 AOSD pts rx w/ TCZ (4-8 mg/kg q4wks). @12 mos clin remission 55%, 6 mos CID 62%, signif drops in CRP, ESR, ferritin & daily pred decr 91% (50 to 4.4 mg; p<0.001). TCZ retention 65%; MAS 7.5% & https://t.co/jtAxrz6ETd
Dr. John Cush
Tweet
Long term F/U of 80 systemic sclerosis pts Rx w/ autologous HSCT. W/ Med. 9.2 yrs F/U progression-free survival = 81%, 72% @5 yrs, & 60% @10 yrs. 18 pts died; death due to HSCT in 6%, SSc progression in 11%, CA in 2 (3%), serious infx 2 (3%), 34 (43%) maintained remission without https://t.co/l6RUf2Zqyw
Video
Podcasts
Individualized PsA Treatment With an IL-23i or a JAKi
DERM on RheumNow PODCAST (October 2026)
Mixed Drinks, Mixed Results (10.30.2026)
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings
Therapeutic Updates
Individualized PsA Treatment With an IL-23i or a JAKi
Sponsored by AbbVie Medical Affairs + Health Impact
In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions
Read Post
Poster Hall
Sponsored by AbbVie Medical Affairs + Health Impact
